Stockholder rights litigation
搜索文档
SELECTQUOTE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges SelectQuote Investors to Contact the Firm Before the October 10th Deadline
Globenewswire· 2025-09-30 05:28
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In SelectQuote (SLQT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in SelectQuote between September 9, 2020 and May 1, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- What’s Happe ...
LIFEMD CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds LFMD Investors a Class Action Has Been Filed and Urges Investors to Contact the Firm
Globenewswire· 2025-09-30 05:23
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In LifeMD (LFMD) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in LifeMD between May 7, 2025 and August 5, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar ...
UNICYCIVE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages Investors in Unicycive to Contact the Firm Regarding Filed Class Action Lawsuit
Globenewswire· 2025-09-30 05:11
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options Before the October 14th Deadline. If you purchased or acquired stock in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 29, 2025 (GLOBE NE ...
LINEAGE URGENT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Lineage Investors of the September 30th Deadline and Urges Investors to Contact the Firm
Globenewswire· 2025-09-29 22:13
诉讼事件概述 - 律师事务所Bragar Eagel & Squire, P C宣布对Lineage Inc (NASDAQ: LINE)提起集体诉讼[7] - 诉讼代表所有购买或收购Lineage首次公开募股(IPO)股份的个人和实体[7] - 投资者申请成为首席原告的截止日期为2025年9月30日[7] 指控核心内容 - 指控称Lineage的IPO注册声明包含关于公司业务、历史财务业绩以及行业趋势的重大虚假陈述[7] - 注册声明声称COVID-19大流行的持续影响“加速了那些对冷库需求产生显著短期影响的趋势,并有可能在未来几年成为行业增长引擎”[7] - 实际情况是公司正处于持续低迷中,客户不仅减少了在疫情期间积累的过多库存,而且转向维持更精简的库存,同时更多冷库供应上线[7] - 由于公司近期在客户群中实施了不可持续的价格上涨,其在入住率和定价能力方面受到特别严重的负面影响[7] 股价表现 - 自大约一年前IPO以来,Lineage股价已跌至每股40美元附近的低点,约为IPO价格的一半[7] 法律程序文件 - 注册声明于2024年6月26日以S-11表格形式向美国证券交易委员会(SEC)提交,经修订后于2024年7月24日被宣布生效[7] - 公司于2024年7月26日以424B4表格形式向SEC提交了IPO招股说明书,该说明书被纳入并构成注册声明的一部分[7]
ENCOMPASS (EHC) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Encompass Health Corporation on Behalf of Encompass Stockholders and Encourages Investors to Contact the Firm
Globenewswire· 2025-09-26 05:39
事件概述 - 律师事务所Bragar Eagel & Squire正在对Encompass Health Corporation可能违反联邦证券法的行为进行调查 [1] - 调查涉及公司是否从事了其他非法商业行为 [1] 调查背景 - 2025年7月15日《纽约时报》文章指控Encompass旗下营利性医院在关键安全指标上表现低于平均水平 [6] - 联邦数据和检查报告显示,Encompass拥有的许多康复机构存在较高的潜在可预防的非计划再入院率 [6] - 有34家Encompass设施被医疗保险评为具有统计上显著更差的潜在可预防再入院率 [6] - 报告揭露了多起导致患者死亡的“惊人错误” [6] 市场影响 - 受该新闻报道影响,Encompass股价在2025年7月15日下跌12.39美元,跌幅达10.4%,收盘报每股107.28美元 [6] - 此次股价下跌对投资者造成了损害 [6]
CTO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Encourages Investors in CTO to Contact the Firm Before October 7th
Globenewswire· 2025-09-25 05:43
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In CTO To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in CTO between February 18, 2021 and June 24, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & ...
KINDERCARE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against KinderCare Learning Companies, Inc. and Encourages Investors to Contact the Firm Before October 14th
Globenewswire· 2025-09-25 05:38
诉讼事件概述 - 全国知名的股东权益律师事务所Bragar Eagel & Squire, P.C.宣布,一项针对KinderCare Learning Companies, Inc. (NYSE: KLC) 的集体诉讼已在美国俄勒冈地区法院波特兰分院提起 [1] - 该诉讼代表所有购买或以其他方式收购了KinderCare首次公开募股(IPO)股份的个人和实体 [1] - 投资者申请成为首席原告的截止日期为2025年10月14日 [1] 指控核心内容 - 针对KinderCare IPO的注册声明被指控存在虚假和/或误导性陈述,未能披露以下信息 [6] - 指控未能披露KinderCare设施内发生了多起儿童虐待、忽视和伤害事件 [6] - 指控未能披露KinderCare并未在其设施提供“最高质量的护理”,且在众多实例中未能提供基本护理、未能达到 childcare 行业的最低标准或未能遵守管理儿童护理的法律法规 [6] 指控的潜在影响 - 据称,由于上述情况,KinderCare面临未披露的重大风险,包括诉讼、不利的监管行动、负面舆论、声誉损害和业务损失 [6] - 自IPO以来,KinderCare股价已跌至接近每股9美元的低点 [6] 律师事务所信息 - Bragar Eagel & Squire, P.C.在纽约、加利福尼亚和南卡罗来纳设有办事处,代表个人和机构投资者处理商业、证券等复杂诉讼 [4]
LINEAGE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Encourages Lineage Investors to Contact the Firm Before September 30th
Globenewswire· 2025-09-25 05:19
诉讼事件概述 - 律师事务所Bragar Eagel & Squire, P C 宣布,已代表所有购买或收购Lineage Inc (NASDAQ: LINE) 首次公开募股(IPO)股份的个人和实体,在美国密歇根州东区地方法院对该公司提起集体诉讼 [8] - 投资者申请成为本案首席原告的截止日期为2025年9月30日 [8] 指控核心内容 - 起诉书指控,Lineage公司的IPO注册声明中包含了关于其业务、历史财务业绩以及据称公司在IPO时面临的行业趋势的重大虚假陈述 [8] - 具体而言,注册声明称,COVID-19疫情的持续影响“加速了那些对冷藏需求产生显著短期影响的趋势,并有可能在未来几年成为行业增长引擎” [8] - 事实是,Lineage当时正处于持续低迷之中,其客户不仅清减了在疫情期间积累的过量库存,而且转向维持更精简的库存水平,同时更多冷藏供应上线 [8] - 由于Lineage近期在其客户群中实施了不可持续的价格上涨,导致其在入住率和定价能力方面受到特别严重的负面影响 [8] 股价表现 - 自大约一年前IPO以来,Lineage公司股价已跌至每股40美元左右的低点,这约为其IPO价格的一半 [8] 公司背景 - 涉事公司为Lineage Inc,股票代码为NASDAQ: LINE [8] - 该公司于2024年6月26日向美国证券交易委员会(SEC)提交了以S-11表格进行的IPO注册声明,经修订后于2024年7月24日被宣布生效 [8] - 该公司于2024年7月26日向SEC提交了以424B4表格进行的IPO招股说明书 [8]
UNICYCIVE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors a Class Action Lawsuit Has Been Filed Against Unicycive Therapeutics, Inc. and Encourages Investors to Contact the Firm
Globenewswire· 2025-09-25 05:03
文章核心观点 - 律师事务所Bragar Eagel & Squire, P.C.宣布,代表在2024年3月29日至2025年6月27日期间购买Unicycive Therapeutics公司证券的投资者,对该公司提起集体诉讼 [8] - 诉讼指控Unicycive公司就其新药申请相关的生产合规准备状态,向投资者做出了虚假和/或误导性陈述,未披露其满足FDA生产合规要求的能力被夸大 [8] - 受FDA审查结果和完全回应函影响,Unicycive公司股价出现两次大幅下跌,累计跌幅显著 [8] 诉讼事件概述 - 集体诉讼已向美国加州北区地方法院提交,投资者申请担任首席原告的截止日期为2025年10月14日 [8] - 诉讼涉及的类别期为2024年3月29日至2025年6月27日 [8] 指控具体内容 - 被告方吹捧了其药物OLC用于治疗透析慢性肾病患者高磷血症的新药申请前景 [8] - 被告方向投资者保证公司已准备好并有能力满足美国FDA的生产合规要求 [8] - 指控称被告方未能披露其满足FDA生产合规要求的能力被夸大 [8] 股价影响事件 - 2025年6月10日,公司公告FDA在其第三方生产供应商处发现cGMP合规缺陷,导致公司股价下跌超过40% [8] - 2025年6月30日,公司公告FDA就OLC新药申请发出完全回应函,再次提及cGMP缺陷,导致公司股价下跌近30%,收盘报每股4.77美元 [8]
ANRO FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Alto Neuroscience, Inc. (ANRO) of the September 19th Deadline
Globenewswire· 2025-09-19 19:23
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alto (ANRO) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Alto between February 2, 2024 and October 22, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Brag ...